Neumora Therapeutics, Inc. (NMRA)
0.427
+0.07
(+20.45%)
USD |
NASDAQ |
Oct 15, 16:00
0.404
-0.02
(-5.39%)
After-Hours: 05:54
Neumora Therapeutics Cash from Operations (TTM) : -180.96M for June 30, 2026
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -180.96M |
| March 31, 2026 | -193.40M |
| December 31, 2025 | -206.44M |
| September 30, 2025 | -208.82M |
| June 30, 2025 | -195.68M |
| March 31, 2025 | -199.43M |
| December 31, 2024 | -182.94M |
| September 30, 2024 | -184.04M |
| Date | Value |
|---|---|
| June 30, 2024 | -198.33M |
| March 31, 2024 | -173.19M |
| December 31, 2023 | -163.28M |
| September 30, 2023 | -142.20M |
| June 30, 2023 | -120.19M |
| March 31, 2023 | -115.75M |
| December 31, 2022 | -114.90M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| BioAge Labs, Inc. | -87.60M |
| ANI Pharmaceuticals, Inc. | 189.47M |
| Corcept Therapeutics, Inc. | 109.70M |
| Veru, Inc. | -26.04M |
| Johnson & Johnson | -- |